Sponsored Content | Webinar | Radiation Therapy| October 13, 2017

WEBINAR: Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation

Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation Therapy, MRI guided RT.

The webinar "Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation" was presented by Parag Parikh, BSE, M.D., associate professor of radiation oncology and biomedical engineering at Washington University in St. Louis, and Percy Lee, M.D., associate professor and vice chair of education for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center. They will share their ongoing experience in using MR-guided radiation therapy to treat pancreatic cancer.

The webinar took place Tuesday, Oct. 24, 2017.

View the archived webinar.

This presentation includes highlights of significant outcomes and treatment protocols currently used with their patients. The webinar will compliment the presenters' poster published at ASTRO17, “Higher Maximum Biologic Effective Dose Utilizing Adaptive MRI Guided Radiation Therapy Improves Survival of Inoperable Pancreatic Cancer Patients," which provided a retrospective review of 42 locally-advanced pancreatic cancer patients treated at four institutions:

- Washington University and Siteman Cancer Center at Barnes-Jewish Hospital, St. Louis

- University of California, Los Angeles Health System and Jonsson Comprehensive Cancer Center

- University of Wisconsin Carbone Cancer Center in Madison

- VU University Medical Center in Amsterdam, Netherlands

The study found that stereotactic dosing regimens guided by MR imaging using the MRIdian system and daily online adaptation had led to significantly prolonged patient survival and resulted in favorably low toxicity.

 

Presenters:

Percy Lee, M.D.Percy Lee, M.D.
Associate Professor Vice Chair, Education Director, Stereotactic Body Radiation Therapy Program
David Geffen School of Medicine at UCLA , UCLA Jonsson Comprehensive Cancer Center

Dr. Lee is an associate professor and vice chair of education for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center. Lee is the clinical director of the stereotactic body radiation therapy (SBRT) program and the chief of service for the thoracic and GI radiation cncology programs in the department. He also serves as the residency training program drector as well as the director for the medical student clerkship. Lee attended the Johns Hopkins University and graduated with the highest honors majoring in biomedical engineering with a concentration in chemical engineering. He attended Harvard Medical School and the Harvard-MIT Health Science and Technology Program where he received his M.D., and graduated magna cum laude. At Harvard, he was also a Howard Hughes Medical Institute fellow. He interned at the Massachusetts General Hospital and received specialty training in radiation oncology from Stanford University School of Medicine.

 

Parag Parikh, BSE, M.DParag Parikh, BSE, M.D
BSE Associate Professor of Radiation Oncology
Washington University School of Medicine in St. Louis 

Parag Parikh, BSE, M.D. is an associate professor of radiation oncology and biomedical engineering at Washington University in St. Louis. He serves as the chief of the gastrointestinal radiation oncology service at Washington University School of Medicine – Barnes Jewish Hospital - Siteman Cancer Center. He sees 400 new patients with pancreatic, liver, rectal and anal cancers per year. He has been routinely using MR-guided radiation therapy for three years, and will be coordinating a multicenter trial with UCLA and other institutions that looks at high dose radiation delivered with MR-guided radiation therapy to treat pancreatic cancer.

 

About ViewRay

ViewRay Inc. (Nasdaq: VRAY) designs, manufactures and markets the MRIdian radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.

ViewRay and MRIdian are registered trademarks of ViewRay Inc.

 

View the archived webinar.

Related Content

Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
MDW Unveils First Radiology Blockchain Platform at RSNA 2018
News | Radiology Business | November 13, 2018
Medical Diagnostic Web (MDW) will debut the first radiology blockchain platform designed to connect all players in the...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...